CMS's GLOBE Drug Pricing Plan Collapses to $400M in Savings, Leaving a Four-Company Test
CMS's GLOBE drug pricing plan's projected savings dropped from $11.9B to $400M, affecting about four manufacturers, including Biogen, Takeda, and Daiichi Sankyo. The reduction is due to exclusions for GARD participants. The final rule may face legal challenges and has raised concerns about its effectiveness.
How this was made
The 30-second read
Why it matters
The rule change signals reduced government leverage in drug pricing, affecting biotech and pharma companies involved.
Market read
The final rule reduces expected savings, likely pressuring the stocks of the remaining manufacturers and signaling tighter drug pricing policy.
What to watch
Potential legal challenges to the rule could create volatility and upside for firms that successfully contest the exclusion.
Background
CMS released a final rule on its GLOBE international reference pricing demonstration, drastically reducing projected savings and limiting coverage to four manufacturers.
Ticker impact
Biogen is one of the four manufacturers still covered by the CMS GLOBE program after the final rule reduced projected savings to $400M.
likely downward pressure as investors price in reduced savings and possible legal challenges.
The final rule sharply cuts expected savings, limiting the program's benefit to Biogen and exposing it to regulatory risk.
Takeda is listed among the four manufacturers remaining in the GLOBE demonstration after the rule change.
potential modest sell pressure as the market reassesses the program's impact on Takeda.
Reduced program scope lowers expected pricing benefits for Takeda.
Market effects
The change may dampen expectations for broader Medicare Part B drug pricing reforms.
U.S. biotech and pharma stocks could see modest pressure.
International manufacturers may reassess participation in U.S. pricing programs.
Counterpoint
If manufacturers negotiate favorable GARD agreements, the limited GLOBE exposure could be offset by other pricing concessions.
Key entities
- companyBiogen
U.S.-listed biotech, one of four manufacturers still covered.
- companyTakeda
Japanese pharma with U.S. ADR, included in the limited GLOBE scope.
- companyDaiichi Sankyo
Japanese pharma with U.S. ADR, part of the remaining GLOBE participants.
